Investors

Corporate Overview

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.

Download Corporate Presentation
Corporate Presentation July 2025
Forward-Looking Statements
Changing the Trajectory of Autoimmune Diseases
LUPKYNIS® - The first FDA-approved oral therapy for the treatment of lupus nephritis
About Lupus Nephritis
Lupus Nephritis (LN) Is Among the Most Severe and Dangerous Complications of Systematic Lupus Erythematosus (SLE)
Proteinuria Is a Significant Risk Factor for Kidney Damage
Even a Single Flare of LN Can Reduce the Lifespan of the Kidney
Proteinuria Reduction Is Associated with Long-Term Renal Protection
LUPKYNIS - A calcineurin-inhibitor immunosuppressant indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis
LUPKYNIS Is a Novel, Structurally Modified CNI that Targets LN with a Dual Mechanism of Action
Robust Clinical Study History
Significantly More Patients on LUPKYNIS Achieved a Complete Renal Response in AURORA 1
LUPKYNIS Rapidly Reduced Proteinuria in Fewer Days in AURORA 1
Adverse Reactions Occurring in ≥3% of Patients Treated with LUPKYNIS 23.7 mg Twice a Day and ≥2% Higher than Placebo in AURORA 1 and AURA-LV
New American College of Rheumatology (ACR) Guideline Support Earlier Usage of LUPKYNIS
2024 ACR Guideline for the Treatment of Lupus Nephritis (LN)
Aritinercept (AUR200) - A dual BAFF/APRIL inhibitor for the potential treatment of autoimmune diseases
Aritinercept Is a Dual BAFF/APRIL Inhibitor
Role of BAFF and APRIL
Aritinercept Is a High Affinity Dual BAFF/APRIL Inhibitor
Aritinercept Potently Inhibits BAFF-and APRIL-Mediated B Cell Proliferation
Aritinercept Reduced Immunoglobulins in Non-Human Primates
Aritinercept Single Ascending Dose (SAD) Study: Design
Aritinercept SAD Study:Safety Summary
Aritinercept SAD Study:Pharmacokinetics Summary
Aritinercept SAD Study: Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins in Humans
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgA
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgM
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgG
Aritinercept SAD Study: Summary and Next Steps
Financial Overview
2024 Financial Highlights
2025 Financial Guidance
Aurinia

Email Alerts

By providing your email address above, you are providing consent to Aurinia Pharmaceuticals Inc. to send you the requested Investor Email Alert updates. For information on how we protect your information, please refer to our Privacy Policy.
Thank you! Your message has been sent!
Oops! There was an error with your submission.

Stock Information

NASDAQ Global Market: AUPH

$10.49

+1.245

/

+13.47%

7.73M

Volume

Last update:
Closed at 08/01/2025 4:00PM ET
Pricing delayed by 15 minutes

Upcoming Events

There are no upcoming events scheduled at this time.

Past Events

Select Year
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Dec 5
-
Dec 5, 2019
Dec 5, 2019 8:30 AM
2019

AURORA Update Conference Call

Press ReleaseWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
Nov 14
-
Nov 14, 2019
Nov 14, 2019 4:30 PM
EDT
2019

Third Quarter 2019 Financial Results Conference Call

Press ReleaseWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
Oct 2
-
Oct 2, 2019
Oct 2, 2019 1:15 PM
EDT
2019

2019 Cantor Global Healthcare Conference

Press ReleaseWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
Sep 9
-
Sep 9, 2019
Sep 9, 2019 12:30 PM
2019

21st Annual H.C. Wainwright Global Investment Conference

Press ReleaseWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
Aug 6
-
Aug 6, 2019
Aug 6, 2019 4:30 PM
EDT
2019

Second Quarter 2019 Financial Results Conference Call

Press ReleaseWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
No Results Found
Please try different keywords or filters.

SEC Filings

Select Year
Form Types
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Date
Filing Type
Description
Download
Date
September 26, 2016
2016
Filing Type
6-K
Description
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Current Reports
Download
Date
August 22, 2016
2016
Filing Type
6-K
Description
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Current Reports
Download
Date
August 15, 2016
2016
Filing Type
6-K
Description
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Current Reports
Download
Date
August 15, 2016
2016
Filing Type
6-K
Description
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Current Reports
Download
Date
August 5, 2016
2016
Filing Type
6-K
Description
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Current Reports
Download
No Results Found
Please try different keywords or filters.

Governance

Committee Charter Documents
Audit Committee Charter
Download
Compensation Committee Charter
Download
Corporate Governance Committee Charter
Download
Disclosure Committee Charter
Download
Governance Documents
Anti-Fraud Policy
Code of Ethics and Conduct
Articles
Certificate and Articles of Amendment
Certificate of Amalgamation
Conformed By-Law No. 2
Corporate Disclosure Policy
Forced Labour Report
Indemnity Policy
Insider Trading Policy
Majority Voting Policy
Mandate of the Board of Directors
Position Description - CFO
Position Description - President - CEO
Terms of Reference - Chairman
Whistleblower Policy

IR Contact

General inquiries can be sent to ir@auriniapharma.com